Synthesis and antiproliferative activity of silybin conjugates with salinomycin and monensin

Chemical Biology and Drug Design

Volumn 86, Issue 6, 2015, Pages 1378-1386

  Antoszczak, Michał ^a   Klejborowska, Greta ^a   Kruszyk, Monika ^a   Maj, Ewa ^b   Wietrzyk, Joanna ^b   Huczyński, Adam ^a  

^a ADAM MICKIEWICZ UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

anticancer activity; molecular hybrids; natural products; polyether antibiotics; silibinin

Indexed keywords

CISPLATIN; DOXORUBICIN; MONENSIN; SALINOMYCIN; SILIBININ; ANTINEOPLASTIC AGENT; PYRAN DERIVATIVE; SILYMARIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DETERMINATION; DRUG MIXTURE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ESTERIFICATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; PRIORITY JOURNAL; 3T3 CELL LINE; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG SCREENING; HEP-G2 CELL LINE; MOUSE; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BALB 3T3 CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HEP G2 CELLS; HUMANS; MICE; MONENSIN; PYRANS; SILYMARIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84956585438     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12602     Document Type: Article

References (45)

1. Bansal Y., Silakari O., (2014) Multifunctional compounds: smart molecules for multifactorial diseases. Eur J Med Chem; 76: 31-42.
2. Godarzi N., Varshochian R., Kamalinia G., Atyabi F., Dinarvand R., (2013) A review of polysaccharide cytotoxic drug conjugates for cancer therapy. Carbohydr Polym; 92: 1280-1293.
3. Patrelli A., Giordano S., (2008) From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem; 15: 422-432.
4. Medina-Franco J.L., Giulianotti M.A., Welmaker G.S., Houghten R.A., (2013) Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today; 18: 495-501.
5. Huczyński A., Antoszczak M., Kleczewska N., Baraniak D., Maj E., Stefańska J., Wietrzyk J., Janczak J., Celewicz L., (2015) Synthesis and biological activity of conjugates of salinomycin and floxuridine. Eur J Med Chem; 93: 33-41.
6. Skiera I., Antoszczak M., Trynda J., Wietrzyk J., Boratyński P., Kacprzak K., Huczyński A., (2015) Antiproliferative activity of polyether antibiotic-Cinchona alkaloid conjugates obtained via click chemistry. Chem Biol Drug Des; 86: 911-917.
7. Lee D.Y., Liu Y., (2003) Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (milk thistle). J Nat Prod; 66: 1171-1174.
8. Gazák R., Walterová D., Křen V., (2007) Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem; 14: 315-338.
9. Cheung C.W., Gibbons N., Johnson D.W., Nicol D.L., (2010) Silibinin-a promising new treatment for cancer. Anticancer Agents Med Chem; 10: 186-195.
10. Li L., Zeng J., Gao Y., He D., (2010) Targeting silibinin in the antiproliferative pathway. Expert Opin Investig Drugs; 19: 243-255.
11. Abenavoli L., Capasso R., Milic N., Capasso F., (2010) Milk thistle in liver diseases: past, present, future. Phytother Res; 24: 1423-1432.
12. Biedermann D., Vavřiková E., Cvak L., Křen V., (2014) Chemistry of silybin. Nat Prod Rep; 31: 1138-1157.
13. Serviddio G., Bellanti F., Stanca E., Lunetti P., Blonda M., Tamborra R., Siculella L., Vendemiale G., Capobianco L., Giudetti A.M., (2014) Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis. Free Radic Biol Med; 73: 117-126.
14. Zarelli A., Romanucci V., Tuccillo C., Federico A., Loguercio C., Gravante R., Di Fabio G., (2014) New silibinin glyco-conjugates: synthesis and evaluation of antioxidant properties. Bioorg Med Chem Lett; 24: 5147-5149.
15. Gazák R., Purchartová K., Marhol P., Živná L., Sedmera P., Valentová K., Kato N., Matsumura H., Kaihatsu K., Křen V., (2010) Antioxidant and antiviral activities of silybin fatty acid conjugates. Eur J Med Chem; 45: 1059-1067.
16. Kelvin D.A. II, Meujo D.A.F., Hamann M.T., (2009) Polyether ionophores: broad-spectrum and promising biologically active molecules for the control of drug-resistant bacteria and parasites. Exp Opin Drug Discov; 4: 109-146.
17. Chapman H.D., Jeffers T.K., Williams R.B., (2010) Forty years of monensin for the control of coccidiosis in poultry. Poult Sci; 89: 1788-1801.
18. Antoszczak M., Rutkowski J., Huczynski A., (2015) Structure and biological activity of polyether ionophores and their semi-synthetic derivatives. In:, Brahmachari G., editor. Bioactive Natural Products: Chemistry and Biology, 1st edn. Weinheim, Germany: Wiley-VCH, Verlag GmbH; p. 107-170. ISBN: 978-3-527-33794-1.
19. Rutkowski J., Brzezinski B., (2013) Structures and properties of naturally occurring polyether antibiotics. BioMed Res Int; 2013:article number: 162513.
20. Huczyński A., (2012) Polyether ionophores-promising bioactive molecules for cancer therapy. Bioorg Med Chem Lett; 22: 7002-7010.
21. Huczyński A., (2012) Salinomycin: a new cancer drug candidate. Chem Biol Drug Des; 79: 235-238.
22. Antoszczak M., Huczyński A., (2015) Anticancer activity of polyether ionophore-salinomycin. Anticancer Agents Med Chem; 15: 575-591.
23. Zhou S., Wang F., Wong E.T., Fonkem E., Hsieh T.C., Wu J.M., Wu E., (2013) Salinomycin: a novel anti-cancer agent with known anti-coccidial activities. Curr Med Chem; 20: 4095-4101.
24. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S., (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell; 138: 645-659.
25. Reya T., Morrison S.J., Clarke M.F., Weissman I.L., (2001) Stem cells, cancer, and cancer stem cells. Nature; 414: 105-111.
26. Calzolari A., Saulle E., De Angelis M.L., Pasquini L., Boe A., Pelacchi F., Ricci-Vitiani L., Baiocchi M., Testa U., (2014) Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines. PLoS ONE; 9:article number e94438.
27. Naujokat C., Steinhart R., (2012) Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol; 00:article number: 950658.
28. Kim W.K., Kim J.H., Yoon K., Kim S., Ro J., Kang H.S., Yoon S., (2012) Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Invest New Drugs; 30: 1311-1318.
29. Kim J.H., Yoo H.I., Kang H.S., Ro J., Yoon S., (2012) Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest. Biochem Biophys Res Commun; 418: 98-103.
30. Wang F., Dai W., Wang Y., Shen M., Chen K., Cheng P., Zhang Y., et al,. (2014) The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma. PLoS ONE; 9:article number e97414.
31. Park W.H., Kim E.S., Jung C.W., Kim B.K., Lee Y.Y., (2003) Monensin-mediated growth inhibition of SNU-C1 colon cancer cells via cell cycle arrest and apoptosis. Int J Oncol; 22: 377-382.
32. Park W.H., Seol J.G., Kim E.S., Kang W.K., Im Y.H., Jung C.W., Kim B.K., Lee Y.Y., (2002) Monensin-mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis. Br J Haematol; 119: 400-407.
33. Park W.H., Kim E.S., Kim B.K., Lee Y.Y., (2003) Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis. Int J Oncol; 23: 197-204.
34. Wood D.J., Rumsby M.G., Warr J.R., (1996) Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells. Cancer Lett; 108: 41-47.
35. Ketola K., Vainio P., Fey V., Kallioniemi O., Iljin K., (2010) Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. Mol Cancer Ther; 9: 3175-3185.
36. Cybulski W., Radko L., Rzeski W., (2015) Cytotoxicity of monensin, narasin and salinomycin and their interaction with silybin in HepG2, LMH and L6 cell cultures. Toxicol In Vitro; 29: 337-344.
37. Huczyński A., Janczak J., Stefańska J., Antoszczak M., Brzezinski B., (2012) Synthesis and antimicrobial activity of amide derivatives of polyether antibiotic-salinomycin. Bioorg Med Chem Lett; 22: 4697-4702.
38. Huczyński A., Janczak J., Antoszczak M., Stefańska J., Brzezinski B., (2012) X-ray, FT-IR, NMR and PM5 structural studies and antibacterial activity of unexpectedly stable salinomycin-benzotriazole intermediate ester. J Mol Struct; 1022: 197-203.
39. Nevozhay D., (2014) Cheburator software for automatically calculating drug inhibitory concentrations from in vitro screening assays. PLoS ONE; 9: e106186.
40. Antoszczak M., Popiel K., Stefańska J., Wietrzyk J., Maj E., Janczak J., Michalska G., Brzezinski B., Huczyński A., (2014) Synthesis, cytotoxicity and antibacterial activity of new esters of polyether antibiotic-salinomycin. Eur J Med Chem; 76: 435-444.
41. Huczyński A., Stefa?ska J., Przybylski P., Brzezinski B., Bartl F., (2008) Synthesis and antimicrobial properties of Monensin A esters. Bioorg Chem Med Lett; 18: 2585-2589.
42. Harker W.G., Slade W.S., Meltzer P.S., Trent J.M., (1989) Multidrug resistance in mitoxantrone HL leukemia cells in the absence of Pglycoprotein overexpression. Cancer Res; 49: 4542-4549.
43. Antoszczak M., Maj E., Stefańska J., Wietrzyk J., Janczak J., Brzezinski B., Huczyński A., (2014) Synthesis, antiproliferative and antibacterial activity of new amides of salinomycin. Bioorg Med Chem Lett; 24: 1724-1729.
44. Rooseboom M., Commandeur J.N., Vermeulen N.P., (2004) Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev; 56: 53-102.
45. Imai T., (2006) Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet; 21: 173-185.